Filtros de búsqueda

Lista de obras de Andreas Hochhaus

A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.

artículo científico publicado en 2015

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

artículo científico publicado en 2014

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

artículo científico publicado en 2007

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

artículo científico publicado en 2009

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached ⬇️

artículo científico publicado el 1 de diciembre de 2003

A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias

article

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

artículo científico publicado en 2002

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

artículo científico publicado en 2013

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

artículo científico publicado en 2007

A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.

artículo científico publicado en 2010

A somatic EZH2 mutation in childhood acute myeloid leukemia

article

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

artículo científico publicado en 2008

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia

article

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis

artículo científico publicado en 2003

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

article

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

artículo científico publicado en 2012

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

article by Y. Wang et al published 1 March 2007 in Blood

Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study

artículo científico publicado en 2002

Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells

artículo científico publicado en 1999

Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer

artículo científico publicado en 2013

Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

artículo científico

Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation

artículo científico publicado en 2014

Adjuvante Therapie des kolorektalen Karzinoms

Advances in the treatment of haematological malignancies: optimal sequence of CML treatment

artículo científico publicado en 2007

Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie

artículo científico publicado en 2002

Akute Leukämien des Erwachsenen

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

artículo científico publicado en 2009

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

artículo científico publicado en 2011

Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin

artículo científico publicado en 2009

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.

artículo científico publicado en 2007

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

artículo científico publicado en 2010

Annexin and Survivin in Locally Advanced Rectal Cancer: Indicators of Resistance to Preoperative Chemoradiotherapy?

article

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice

artículo científico publicado en 2013

AraC-based pharmacotherapy of chronic myeloid leukaemia

artículo científico publicado en 2001

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

artículo científico publicado en 2017

Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.

artículo científico publicado en 2010

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia

artículo científico publicado en 2016

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

article published in 2005

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

artículo científico publicado en 2011

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

artículo científico publicado en 2011

BCR-ABL mutations in chronic myeloid leukemia

artículo científico

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment

artículo científico publicado en 2011

BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-α

artículo científico publicado en 1998

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

artículo científico publicado en 2015

Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leuk

Biomarker candidates for the detection of an infectious etiology of febrile neutropenia

artículo científico publicado en 2015

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

artículo científico publicado en 2017

Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie

artículo científico publicado en 2011

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial

artículo científico publicado en 2007

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial

artículo científico publicado en 2004

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

artículo científico publicado en 2007

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

artículo científico publicado en 2008

Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

artículo científico publicado en 2012

Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements

artículo científico publicado en 2016

Cause and management of therapy resistance

scientific article published on September 2009

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients

artículo científico

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib

artículo científico publicado en 2008

Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

artículo científico publicado en 2005

Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

artículo científico publicado en 2009

Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.

artículo científico publicado en 2009

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

artículo científico publicado en 2009

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.

artículo científico publicado en 2007

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

artículo científico publicado en 2012

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

artículo científico publicado en 2009

Chronic Myelogeneous Leukemia

Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors

artículo científico publicado en 2006

Chronic myelogenous leukemia: ESMO Clinical Recommendations for the diagnosis, treatment and follow-up

Chronic myelogenous leukemia: molecular and cellular aspects

artículo científico publicado en 1998

Chronic myeloid leukaemia

artículo científico publicado en 2007

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2017

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

article published in 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

artículo científico publicado en 2001

Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha

artículo científico publicado en 2003

Chronic myeloid leukemia: a model for oncology

artículo científico publicado en 2005

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

artículo científico publicado en 2009

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression

artículo científico publicado en 2012

Chronic myeloproliferative diseases. Diagnosis and therapy

artículo científico publicado en 2003

Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease

artículo científico publicado en 2016

Chronische myeloische Leukämie

article published in 2012

Chronische myeloische Leukämie

Chronische myeloische Leukämie

Chronische myeloische Leukämie mit Management-Empfehlungen des European LeukemiaNet

Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature

artículo científico

Clinical resistance to imatinib: mechanisms and implications

artículo científico publicado en 2004

Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy

artículo científico publicado en 2009

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

article

Clonal T-LGL population mimicking leukemia in Felty's syndrome--part of a continuous spectrum of T-LGL proliferations?

artículo científico publicado en 2013

Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha

artículo científico publicado en 2005

Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.

artículo científico publicado en 2009

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myelo

artículo científico publicado en 2008

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

artículo científico publicado en 2002

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients

artículo científico publicado en 2016

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

artículo científico publicado en 2005

Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib

artículo científico publicado en 2004

Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma

artículo científico publicado en 2013

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

artículo científico publicado en 2015

Comprehensive mutational profiling in advanced systemic mastocytosis

artículo científico publicado en 2013

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

artículo científico publicado en 2012

Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997.

artículo científico publicado en 1998

Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

artículo científico publicado en 2006

Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group

artículo científico publicado en 2002

Current treatment concepts of CML.

scientific article published on January 2011

Current trends in the management of chronic myelogenous leukemia

artículo científico publicado en 2000

Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation

artículo científico publicado en 1998

Cytogenetic and molecular characterization of simultaneous chronic and acute myelocytic leukemia

artículo científico publicado en 2003

Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia

article

Dasatinib

artículo científico publicado en 2010

Dasatinib

artículo científico

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

artículo científico publicado en 2007

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

artículo científico publicado en 2016

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

artículo científico publicado en 2010

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

artículo científico publicado en 2009

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

artículo científico publicado en 2006

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

artículo científico publicado en 2008

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

article

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

artículo científico publicado en 2007

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

article

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

artículo científico publicado en 2011

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

scientific article published on 24 September 2009

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2010

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

artículo científico publicado en 2009

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis

artículo científico publicado en 2021

Deep molecular response in chronic myeloid leukemia.

artículo científico publicado en 2016

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

artículo científico publicado en 2013

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

artículo científico publicado en 2018

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

artículo científico

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

artículo científico publicado en 2008

Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored?

Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors

artículo científico publicado en 2010

Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment

artículo científico publicado en 2009

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

artículo científico publicado en 2003

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

scientific article published on 25 April 2016

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib

artículo científico publicado en 2009

Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia

article

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

artículo científico publicado en 2007

Diagnostik der chronischen myeloischen Leukämie - Charakteristisches Blutbild, Knochenmarkaspiration und Zytogenetik

Diagnostik und Therapie der CML

Diagnostik und Therapie der chronischen myeloischen Leukämie

Die hämophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik

Die megakaryozytäre Myelose — Klinik, Morphologie und Plättchenfunktion

artículo científico publicado en 1989

Different clones of acute leukemia after successful treatment of Hodgkin's disease.

artículo científico publicado en 2014

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study

artículo científico publicado en 2013

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

artículo científico publicado en 2018

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

artículo científico publicado en 2014

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

artículo científico publicado en 2020

Dose-dependent severe cutaneous reactions to imatinib

scientific article published on April 2003

Drug therapy of chronic myeloid leukemia

artículo científico publicado en 2002

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

article by R. Hehlmann et al published 1 June 2007 in Blood

Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

artículo científico publicado en 2018

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

artículo científico publicado en 2006

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

artículo científico publicado en 2003

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

artículo científico publicado en 2008

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure

article

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

artículo científico publicado en 2010

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

article

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia

scientific article published on 14 August 2019

EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.

artículo científico publicado en 2016

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

artículo científico publicado en 2012

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

artículo científico publicado en 2013

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

artículo científico publicado en 2002

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

artículo científico publicado en 2013

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study

artículo científico publicado en 2013

Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study

artículo científico publicado en 2013

Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).

artículo científico publicado en 2014

Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma

artículo científico publicado en 2010

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

artículo científico publicado en 2008

Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.

artículo científico publicado en 2018

Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia

artículo científico publicado en 2015

Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma.

artículo científico publicado en 2007

Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML)

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity

artículo científico publicado en 2011

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells

artículo científico publicado en 2007

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

artículo científico publicado en 2009

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2014

Erratum: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

scholarly article published in Leukemia

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

scholarly article published in Leukemia

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

scholarly article published in Leukemia

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

artículo científico publicado en 2013

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

artículo científico publicado en 2010

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

artículo científico publicado en 2016

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

artículo científico publicado en 2013

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

artículo científico publicado en 2006

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

artículo científico

Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.

artículo científico publicado en 2000

Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia

artículo científico publicado en 2001

Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha

article

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

artículo científico publicado en 2017

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

artículo científico publicado en 2018

Expression of the LH2 gene in chronic myeloid leukaemia cells.

artículo científico publicado en 1996

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

artículo científico publicado en 2007

Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells

artículo científico publicado en 2007

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

artículo científico publicado en 2014

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

artículo científico publicado en 2007

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

artículo científico publicado en 2016

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

artículo científico publicado en 2006

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

artículo científico publicado en 2003

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

artículo científico publicado en 2011

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

artículo científico publicado en 2015

Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis

scholarly article by Wibke Göpel et al published 4 August 2016 in Annals of Hematology

Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy

artículo científico publicado en 2002

Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO)

Gender aspects in chronic myeloid leukemia: long-term results from randomized studies

artículo científico publicado en 2005

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.

artículo científico publicado en 2006

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

artículo científico publicado en 2006

Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia

artículo científico publicado en 2003

Genomic instability in context of the chromosomal theory.

artículo científico publicado en 2008

Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA.

artículo científico publicado en 2013

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

artículo científico publicado en 2007

Harmonization of molecular monitoring of CML therapy in Europe

artículo científico publicado en 2009

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

artículo científico publicado en 2002

Hematological side effects of tyrosine kinase inhibition using imatinib

artículo científico publicado en 2006

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia

High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study

artículo científico publicado en 2002

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms

artículo científico publicado en 2022

How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

artículo científico publicado en 2005

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

artículo científico publicado en 2010

Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).

artículo científico

Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

artículo científico publicado en 2012

Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.

artículo científico publicado en 2007

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

artículo científico publicado en 2007

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

article

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

artículo científico publicado en 2017

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

artículo científico publicado en 2002

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

artículo científico publicado en 2002

Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

artículo científico publicado en 2008

Imatinib restores expression of CD62L in BCR-ABL-positive cells

artículo científico publicado en 2003

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

artículo científico publicado en 2004

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

artículo científico publicado en 2011

Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia

artículo científico publicado en 2016

Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia

artículo científico publicado en 2013

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

artículo científico publicado en 2011

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

artículo científico publicado en 2017

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus

artículo científico publicado en 2004

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

artículo científico publicado en 2015

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

artículo científico publicado en 2016

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

artículo científico publicado en 2015

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

article published in 2013

Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization

artículo científico publicado en 2002

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

artículo científico publicado en 2005

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

artículo científico publicado en 2010

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

scholarly article by Timothy P Hughes et al published January 2019 in Haematologica

Induction of centrosome and chromosome aberrations by imatinib in vitro

artículo científico publicado en 2005

Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO).

artículo científico publicado en 2016

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

artículo científico publicado en 2012

Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology

artículo científico publicado en 2020

Interdisziplinarität am Beispiel gastrointestinaler Tumoren

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.

artículo científico publicado en 2015

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

artículo científico publicado en 2003

Interferon in chronic myeloid leukemia. A workshop report

artículo científico publicado en 1993

Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.

artículo científico publicado en 1999

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

artículo científico publicado en 2002

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

artículo científico publicado en 2008

International standardisation of quantitative real-time RT-PCR for BCR-ABL

article

Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study

artículo científico publicado en 2005

Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats

artículo científico publicado en 2006

Isoform localization of Dectin-1 regulates the signaling quality of anti-fungal immunity

artículo científico publicado en 2017

Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2012

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

artículo científico publicado en 2007

KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

artículo científico publicado en 2010

Key Data Elements in Myeloid Leukemia

artículo científico publicado en 2016

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

article

Klinische Forschung im „European LeukemiaNet”

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

artículo científico publicado en 2015

Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD).

artículo científico publicado en 2013

Lack of clinical efficacy of imatinib in metastatic melanoma

artículo científico publicado en 2005

Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome

Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias

artículo científico

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

artículo científico publicado en 2016

Leukämien als Modellerkrankungen für individualisierte Therapien

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

artículo científico publicado en 2011

Liposomal encapsulated anti-cancer drugs

artículo científico publicado en 2005

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

artículo científico publicado en 2017

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

artículo científico publicado en 2016

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

artículo científico publicado en 2015

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

artículo científico publicado en 2013

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

artículo científico publicado en 2015

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

artículo científico publicado en 2014

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

artículo científico publicado en 2010

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

artículo científico publicado en 2006

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia

artículo científico publicado en 2011

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

artículo científico publicado en 2011

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

artículo científico publicado en 2007

Lower gastrointestinal bleeding in a patient with Crohn’s disease and plasma cell leukemia in remission

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

artículo científico publicado en 2016

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

article by M Agrawal et al published 10 January 2014 in Leukemia

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

artículo científico publicado en 2012

Magnetic particle spectroscopy allows precise quantification of nanoparticles after passage through human brain microvascular endothelial cells

artículo científico publicado en 2016

Management of Bcr-Abl-positive leukemias with dasatinib

artículo científico publicado en 2007

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

scientific article published on 23 September 2010

Measurement of piperacillin plasma concentrations in cancer patients with suspected infection

artículo científico publicado en 2017

Minimal Residual Disease in Hematological Malignancies

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

artículo científico publicado en 2011

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

artículo científico publicado en 2005

Minimal residual disease in chronic myeloid leukaemia patients

artículo científico publicado en 2002

Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study

artículo científico publicado en 2014

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2012

Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.

artículo científico publicado en 2013

Molecular Monitoring of Residual Disease in Chronic Myelogenous Leukemia Patients After Therapy ⬇️

artículo científico publicado el 1 de enero de 1998

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

artículo científico publicado en 2002

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms

artículo científico publicado en 2017

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

artículo científico

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

artículo científico publicado en 2003

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia

scientific article published on March 2010

Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance

artículo científico publicado en 2004

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

artículo científico publicado en 2014

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

artículo científico publicado en 2006

Monitoring of minimal residual disease in chronic myeloid leukemia

artículo científico publicado en 2004

Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)

artículo científico publicado en 1991

Mutational analysis of the p15 and p16 genes in acute leukaemias

artículo científico publicado en 1996

New perspectives with interferon alpha. The German CML study group experience

artículo científico publicado el 1 de enero de 1994

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Nicole Muller-Bérat Killmann 1932-2014 Leukemia pioneer

artículo científico publicado en 2014

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

artículo científico publicado en 2007

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

artículo científico publicado en 2007

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

artículo científico publicado en 2017

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

artículo científico publicado en 2006

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

artículo científico publicado en 2012

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

artículo científico publicado en 2011

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

artículo científico publicado en 2015

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article published on 15 March 2013

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.

artículo científico publicado en 2011

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

artículo científico publicado en 2010

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

artículo científico publicado en 2010

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

artículo científico publicado en 2011

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

artículo científico publicado en 2012

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2017

Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia

artículo científico publicado en 2003

Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia

artículo científico publicado en 2003

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

artículo científico publicado en 2011

Novel myelofibrosis treatment strategies: potential partners for combination therapies

artículo científico publicado en 2014

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

artículo científico publicado en 2003

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

artículo científico publicado en 2014

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.

artículo científico publicado en 2012

Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies

artículo científico publicado en 2017

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2010

Optimizing tolerability of TKI therapy in CML.

artículo científico publicado en 2014

Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkin’s lymphoma

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.

artículo científico publicado en 2016

Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

artículo científico publicado en 2017

Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism

artículo científico publicado en 2002

Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial

artículo científico publicado en 2008

PTEN opposes negative selection and enables oncogenic transformation of pre-B cells

artículo científico publicado en 2016

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

artículo científico publicado en 2018

Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib

artículo científico publicado en 2003

Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track

artículo científico publicado en 2013

Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review

artículo científico publicado en 2014

Paraneoplastische Gerinnungsstörungen

Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors

artículo científico publicado en 2013

Paul Ehrlichs „magic bullets“

Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial

artículo científico publicado en 2005

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer

artículo científico publicado en 2004

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

artículo científico publicado en 2010

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

artículo científico publicado en 2013

Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer

artículo científico publicado en 2005

Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer

artículo científico publicado en 2006

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.

artículo científico publicado en 2013

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

artículo científico publicado en 2012

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib

artículo científico publicado en 2008

Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial

artículo científico publicado en 2017

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia

artículo científico publicado en 2016

Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia

artículo científico publicado en 2014

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

artículo científico publicado en 2016

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

artículo científico publicado en 2018

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation

artículo científico publicado en 2012

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

artículo científico publicado en 2016

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

artículo científico publicado en 2011

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

article

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

artículo científico publicado en 2013

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

artículo científico publicado en 2012

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors

artículo científico publicado en 2009

Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.

artículo científico publicado en 2016

Prognostic factors in chronic myeloid leukemia (CML).

artículo científico publicado en 2008

Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia

artículo científico publicado en 2001

Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib

Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach.

artículo científico publicado en 2000

Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.

artículo científico publicado en 1995

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

artículo científico publicado en 2012

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea

artículo científico publicado en 2003

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

artículo científico publicado en 1994

Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group

artículo científico publicado el 1 de abril de 1997

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2013

Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia.

artículo científico publicado en 1997

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

artículo científico publicado en 2013

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

artículo científico publicado en 2006

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation

artículo científico publicado en 2001

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

artículo científico publicado en 2011

Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation.

artículo científico publicado en 2011

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

article

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

artículo científico publicado en 2016

Reply to H. Kantarjian et al.

artículo científico publicado en 2014

Reply to Inokuchi et al

Reply to V. Pitini et al

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications

artículo científico publicado en 2008

Resistance to targeted therapy in chronic myelogenous leukemia

artículo científico publicado en 2007

Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells

artículo científico publicado en 2002

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

artículo científico publicado en 2005

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

artículo científico publicado en 2016

Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

artículo científico publicado en 2011

Response to Ho-Wan Ip and Chi-Chiu.

artículo científico publicado en 2015

Response-related predictors of survival in CML.

artículo científico

Response: Drug treatment and allografting as first-line therapy in young patients with CML

Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?

article

Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma

artículo científico publicado en 2010

Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer.

artículo científico publicado en 2005

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

artículo científico publicado en 2015

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).

artículo científico publicado en 2002

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

artículo científico publicado en 2015

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study

artículo científico publicado en 2008

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

artículo científico

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

artículo científico publicado en 2010

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

artículo científico publicado en 2007

Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene

artículo científico publicado en 2004

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

artículo científico publicado en 2016

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology

artículo científico publicado en 2001

Short-Term Application of Magnetic Core-Shell Nanoparticles—Effect on Immune Cells

article

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

article

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

artículo científico

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2009

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

artículo científico publicado en 2003

Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia

artículo científico publicado en 2004

Standardized definitions of molecular response in chronic myeloid leukemia.

artículo científico

Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.

artículo científico publicado en 2011

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

artículo científico publicado en 2013

Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib

article by H Menzel et al published 23 April 2007 in Bone Marrow Transplantation

Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin.

artículo científico publicado en 2016

Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male

artículo científico publicado en 2003

Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles

Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia

artículo científico publicado en 2008

Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular spheroids

article

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

artículo científico publicado en 2005

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

artículo científico publicado en 2010

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

artículo científico publicado en 2014

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

artículo científico publicado en 2015

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

artículo científico publicado en 2003

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

artículo científico publicado en 2013

The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.

artículo científico publicado en 2013

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells

artículo científico publicado en 2012

The European LeukemiaNet: achievements and perspectives

artículo científico publicado en 2010

The German CML Study, Comparison of Busulfan vs. Hydroxyurea vs. Interferon alpha and Establishment of Prognostic Score 1

article

The German competence network ‘Acute and chronic leukemias’

article

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.

artículo científico publicado en 2013

The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians

artículo científico publicado en 2006

The concept of treatment-free remission in chronic myeloid leukemia

artículo científico publicado en 2016

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

artículo científico

The molecular anatomy of the FIP1L1-PDGFRA fusion gene.

artículo científico publicado en 2008

The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.

artículo científico publicado en 2010

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

artículo científico publicado en 2007

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

artículo científico publicado en 2012

The results of imatinib therapy for patients with primary eosinophilic disorders.

artículo científico publicado en 2006

The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.

artículo científico publicado en 2005

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

artículo científico publicado en 2005

Therapie der chronischen myeloischen Leukämie bei älteren Patienten

Therapie von Hirnmetastasen und Meningeosis neoplastica

Therapiemonitoring der chronischen myeloischen Leukämie - Hämatologische, zytogenetische und molekulare Daten konsequent erheben

Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia

article published in 2011

Therapy of chronic myelogenous leukemia in 2004

artículo científico publicado en 2004

Therapy of older persons with acute myeloid leukemia.

artículo científico publicado en 2015

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

artículo científico publicado en 2011

Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer

artículo científico publicado en 2009

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

artículo científico

Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.

artículo científico publicado en 2006

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

artículo científico publicado en 2016

Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?

artículo científico publicado en 2003

Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?

artículo científico publicado en 2007

Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient

artículo científico publicado en 2003

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α

artículo científico publicado en 1995

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

artículo científico publicado en 2014

What is the (p-) value of the P-value?

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

artículo científico publicado en 2005

XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, July 13-18 Mannheim/Heidelberg, Germany, 1997.

artículo científico publicado en 1998

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

artículo científico publicado en 2013

Zielgerichtete Therapien bei hämatologischen Erkrankungen

[Acute leukemia in adults].

artículo científico publicado en 2015

[Chronic myelogenous leukemia].

artículo científico publicado en 2015

[Tailored management of chronic myeloid leukemia].

artículo científico publicado en 2013

e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?

article

mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda